Displaying 1 - 20 of 24 tests
E-Cadherin
E Cadherin is an adhesion protein that is expressed in cells of epithelial lineage. It stains positively in glandular epithelium, as well as adenocarcinomas of the lung, G.I. tract and ovary. It is useful in distinguishing adenocarcinoma from mesothelioma. It is also positive in some thyroid
Immunohistochemistry (IHC)
EBER
This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV
In Situ Hybridization (ISH)
EBV (LMP1)
This antibody reacts strongly with Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with some EBV-associated neoplasms, particularly EBV-associated Hodgkin lymphoma.
Immunohistochemistry (IHC)
EGFR
Epidermal Growth Factor Receptor (EGFR) overexpression can occur in a variety of tumor types, including breast, prostate, ovarian, brain, lung and predominantly squamous cell carcinomas. Tumors that express EGFR are associated with a poor prognosis and a shorter disease-free survival. Most colon
Immunohistochemistry (IHC)
EGFR (E746-A750del specific)
Epidermal Growth Factor Receptor (EGFR) is a 170 kDa transmembrane receptor tyrosine kinase that belongs to the HER/ErbB protein family. Somatic mutations in the tyrosine kinase domain of EGFR are present in a subset of lung adenocarcinomas. Two types of mutations account for approximately 90% of
Immunohistochemistry (IHC)
EGFR (L858R mutant specific)
Epidermal Growth Factor Receptor (EGFR) is a 170 kDa transmembrane receptor tyrosine kinase that belongs to the HER/ErbB protein family. Somatic mutations in the tyrosine kinase domain of EGFR are present in a subset of lung adenocarcinomas. Two types of mutations account for approximately 90% of
Immunohistochemistry (IHC)
EGFR Amplification
Probes: EGFR (7p11.2) | Centromere 7 Disease(s): Brain, lung, colorectal, gastric, breast cancers
FISH
EGFR Mutation Analysis
Bi-directional sequencing of exons 18-21 of the EGFR gene for detection of EGFR-activating mutations and TKI resistance mutations (including T790M) in these exons. Tumor enrichment is performed before extraction. Testing is approved for specimens from the state of New York.
Molecular
EGFR T790M Germline Mutation Analysis
Bidirectional sequence analysis of EGFR exon 20 in peripheral blood for detection of T790M germline mutation. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures
Molecular
EGFRvIII Analysis
The EGFRvIII Analysis test is a real-time RT-PCR assay that is capable of detecting the EGFRvIII mutation that results from an inframe deletion of 801 base pairs spanning exons 2-7 of the coding sequence.
Molecular
eIF4E
eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altered in various cancers and has been associated with worse survival. High expression of eIF4E is associated with adverse tumor characteristics and predicts poor breast cancer-specific survival.
Immunohistochemistry (IHC)
Elastic Stain
Special stain.
Immunohistochemistry (IHC)
EMA
Epithelial Membrane Antigen (EMA) antibody stains normal and neoplastic cells from various tissues, including mammary epithelium, sweat glands and squamous epithelium. Hepatocellular carcinoma, adrenal carcinoma and embryonal carcinomas are consistently EMA negative, therefore, keratin positivity
Immunohistochemistry (IHC)
Eosinophilia FISH Panel
Probes: PDGFRa, CHIC2, FIP1L1 (4q12) | PDGFRb (5q33) | FGFR1 (8p11) | CBFB inv(16), t(16;16) | Probes may be ordered separately. Disease(s): Lymphoid and myeloid neoplasms with eosinophilia, including: Chronic eosinophilic leukemia, eosinophilia, MPN, AML-NOS, lymphoblastic lymphoma, CMML, AML with
FISH
EPCAM Mutation & Del/Dup Analysis
This test is performed by sequencing the entire EPCAM gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch
Molecular
ER
Estrogen Receptor (ER) belongs to a superfamily of nuclear hormone receptors and is expressed in about 85% of invasive breast cancers. There are two known isoforms of estrogen receptor, ERα and ERß. It is a weak prognostic factor but a strong predictive factor for response to endocrine therapies,
Immunohistochemistry (IHC)
ERCC1
The Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 1 (ERCC1) polypeptide is required for nucleotide excision repair (NER) of damaged DNA. Elevated levels of ERCC1 have also been reported in cisplatin-resistant cells.
Immunohistochemistry (IHC)
ERG
ERG oncoprotein expression has been shown to be a highly specific marker for prostate cancer. Given the lack of ERG expression in a wide variety of normal epithelial tissues and tumors, detection of ERG by IHC is a valuable tool for diagnosing prostate cancer or determining prostatic origin. ERG is
Immunohistochemistry (IHC)
Erythroid-Mega Add-On Flow Panel
Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD41, cCD61, CD13, CD34, CD45, CD71, CD117, and CD235a (8 markers).
Flow Cytometry
ETV6 Mutation Analysis
Bi-directional sequencing of exons 2-7 of the ETV6 gene (formerly called TEL). This assay detects sequence variants rather than ETV6 translocations.
Molecular